SecBot SecBot
144 ·Filed Jun 1, 2026

MIRM

Mirum Pharmaceuticals, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed5mo ago SEC0001950047-26-005448
Form 144, notice of proposed sale of securities
Actionable Insight • Neutral

This is a routine insider monetization via option exercise, not a distress signal. The sale is moderate in size relative to the insider's total position and the company's $6.2B market cap. Monitor for actual Form 4 filings to confirm execution. No immediate trading action warranted.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$92.17
T+0 close · Jun 1, 2026 · via day close
Latest settled
+6.88%
T+60 · $98.51
Vs SPY
+5.76%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 2 $92.17entry
  2. T+1 · 6mo ago −0.36%α +0.36% · $91.84
  3. T+5 · 5mo ago +3.59%α +6.56% · $95.48
  4. T+20 · 5mo ago +30.69%α +32.26% · $120.46
  5. T+60 · 3mo ago +6.88%α +5.76% · $98.51

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Christopher Peetz, an officer and director of Mirum Pharmaceuticals, filed a Form 144 notice of intent to sell 30,000 shares of common stock, with an approximate market value of $2.88 million based on the filing date. The shares were acquired via stock option exercise on the same day, suggesting a cashless exercise-and-sell transaction. While the sale is modest relative to Peetz's remaining holdings (40,985 shares worth ~$3.77 million as of March 2026), the filing signals insider intent to monetize equity ahead of any potential catalyst.

Key Facts

  • Insider Christopher Peetz (officer and director) filed Form 144 to sell 30,000 shares
  • Sale value approximately $2.88 million based on filing date
  • Shares were acquired via stock option exercise on June 1, 2026
  • Peetz retains 40,985 shares (worth ~$3.77 million as of March 2026)
  • Sale represents ~42% of total holdings (30,000 / 70,985 shares)
  • No lock-up expiration or earnings catalyst mentioned in filing

Financial Impact

Proposed sale of 30,000 shares valued at ~$2.88 million, representing ~42% of insider's disclosed holdings

insider holdingsdilution

Risk Factors

  • Insider may be reducing exposure ahead of a catalyst or earnings event not disclosed in this filing
  • Form 144 is intent to sell; actual sale may not occur or may differ in size/timing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-005448
Document: 0001950047-26-005448-index.html0001950047-26-005448
Document: 0001950047-26-005448.txt0001950047-26-005448

US Market Status

Market Closed · Opens in 8h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 1, 2026